Aberrant expression of CDK5 infers poor outcomes for nasopharyngeal carcinoma patients

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 7, 2015, Pages 8066-8074

  Zhang, Xin ^a   Zhong, Tengfei ^a   Dang, Yiwu ^a   Li, Zuyun ^a   Li, Ping ^a   Chen, Gang ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

CDK5; EGFR; Immunohistochemistry; Nasopharyngeal carcinoma; P53

Indexed keywords

CDK5 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 5; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P53; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; BIOPSY; CANCER STAGING; CARCINOMA; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; COMPARATIVE STUDY; ENZYMOLOGY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MORTALITY; NASOPHARYNGEAL NEOPLASMS; PATHOLOGY; RISK FACTOR; SECONDARY; TISSUE MICROARRAY; UPREGULATION; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BIOPSY; CARCINOMA; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; CYCLIN-DEPENDENT KINASE 5; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK FACTORS; TISSUE ARRAY ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION; YOUNG ADULT;

EID: 85012991903     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Yuan T, Zhang H, Liu B, Zhang Q, Liang Y, Zheng R, Deng J and Zhang X. Expression of MTA1 in nasopharyngeal carcinoma and its correlation with prognosis. Med Oncol 2014; 31: 330.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
3. Lai SZ, Li WF, Chen L, Luo W, Chen YY, Liu LZ, Sun Y, Lin AH, Liu MZ and Ma J. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys 2011; 80: 661-668.
4. Zeng L, Tian YM, Sun XM, Chen CY, Han F, Xiao WW, Deng XW and Lu TX. Late toxicities after intensity-modulated radiotherapy for nasopharyngeal carcinoma: patient and treatment-related risk factors. Br J Cancer 2014; 110: 49-54.
5. Xiao WW, Huang SM, Han F, Wu SX, Lu LX, Lin CG, Deng XW, Lu TX, Cui NJ and Zhao C. Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: long-term results of a phase 2 study. Cancer 2011; 117: 1874-1883.
6. Wang J, Shi M, Hsia Y, Luo S, Zhao L, Xu M, Xiao F, Fu X, Li J, Zhou B and Long X. Failure patterns and survival in patients with nasopharyngeal carcinoma treated with intensity modulated radiation in Northwest China: a pilot study. Radiat Oncol 2012; 7: 2.
7. Meyerson M, Enders GH, Wu CL, Su LK, Gorka C, Nelson C, Harlow E and Tsai LH. A family of human cdc2-related protein kinases. EMBO J 1992; 11: 2909-2917.
8. Liu JL, Wang XY, Huang BX, Zhu F, Zhang RG and Wu G. Expression of CDK5/p35 in resected patients with non-small cell lung cancer: relation to prognosis. Med Oncol 2011; 28: 673-678.
9. Cao L, Zhou J, Zhang J, Wu S, Yang X, Zhao X, Li H, Luo M, Yu Q, Lin G, Lin H, Xie J, Li P, Hu X, Zheng C, Bu G, Zhang Y, Xu H, Yang Y, Huang C and Zhang J. Cyclin dependent kinase 5 decreases in gastric cancer and its nuclear accumulation suppresses gastric tumorigenesis. Clin Cancer Res 2015; 21: 1419-1428.
10. Wissing MD, Dadon T, Kim E, Piontek KB, Shim JS, Kaelber NS, Liu JO, Kachhap SK and Nelkin BD. Small-molecule screening of PC3 prostate cancer cells identifies tilorone dihydrochloride to selectively inhibit cell growth based on cyclin-dependent kinase 5 expression. Oncol Rep 2014; 32: 419-424.
11. Zhang P, Wu SK, Wang Y, Fan ZX, Li CR, Feng M, Xu P, Wang WD and Lang JY. p53, MDM2, eIF4E and EGFR expression in nasopharyngeal carcinoma and their correlation with clinicopathological characteristics and prognosis: A retrospective study. Oncol Lett 2015; 9: 113-118.
12. Huang S, He R, Rong M, Dang Y and Chen G. Synergistic effect of MiR-146a mimic and cetuximab on hepatocellular carcinoma cells. Biomed Res Int 2014; 2014: 384121.
13. Chen G, Umelo IA, Lv S, Teugels E, Fostier K, Kronenberger P, Dewaele A, Sadones J, Geers C and De Greve J. miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells. PLoS One 2013; 8: e60317.
14. Chen G, Noor A, Kronenberger P, Teugels E, Umelo IA and De Greve J. Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib. PLoS One 2013; 8: e59708.
15. Jiang YQ, Zhong TF, Dang YW, Zou LS, Yang L, Yang X and Chen G. Overexpression and clinicopathological contribution of DcR3 in bladder urothelial carcinoma tissues. Asian Pac J Cancer Prev 2014; 15: 9137-9142.
16. Chen G and Luo D. Expression of decoy receptor 3 in liver tissue microarrays. Natl Med J India 2008; 21: 275-278.
17. Chen G, Rong M and Luo D. TNFRSF6B neutralization antibody inhibits proliferation and induces apoptosis in hepatocellular carcinoma cell. Pathol Res Pract 2010; 206: 631-641.
18. Yang M, Chen G, Dang Y and Luo D. Significance of decoy receptor 3 in sera of hepatocellular carcinoma patients. Ups J Med Sci 2010; 115: 232-237.
19. Huang S, Chen G, Dang Y and Chen LH. Overexpression of DcR3 and its significance on tumor cell differentiation and proliferation in glioma. ScientificWorldJournal 2014; 2014: 605236.
20. Mao D and Hinds PW. p35 is required for CDK5 activation in cellular senescence. J Biol Chem 2010; 285: 14671-14680.
21. Catania A, Urban S, Yan E, Hao C, Barron G and Allalunis-Turner J. Expression and localization of cyclin-dependent kinase 5 in apoptotic human glioma cells. Neuro Oncol 2001; 3: 89-98.
22. Huang TR, Zhang SW, Chen WQ, Deng W, Zhang CY, Zhou XJ and Zhai RH. Trends in nasopharyngeal carcinoma mortality in China, 1973-2005. Asian Pac J Cancer Prev 2012; 13: 2495-2502.
23. Berg M and Soreide K. EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy. Discov Med 2012; 14: 207-214.
24. Esteve A, Lehman T, Jiang W, Weinstein IB, Harris CC, Ruol A, Peracchia A, Montesano R and Hollstein M. Correlation of p53 mutations with epidermal growth factor receptor overexpression and absence of mdm2 amplification in human esophageal carcinomas. Mol Carcinog 1993; 8: 306-311.
25. Hoe SL, Lee ES, Khoo AS and Peh SC. p53 and nasopharyngeal carcinoma: a Malaysian study. Pathology 2009; 41: 561-565.